Consequently, the development of anti-CD47 antibodies is warranted, and anti-CD47 therapy has been shown to enhance the efficacy of PD-1 and CTLA-4 inhibitors in esophageal squamous cell carcinoma (ESCC) (49, 50). Here, CD47 is linked to esophageal squamous cell carcinoma.